Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle
Authors
Keywords
-
Journal
Nature Communications
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-03-19
DOI
10.1038/ncomms4511
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma
- (2013) Jilong Yang et al. BMC Medical Genomics
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
- (2013) Warren A. Whyte et al. CELL
- Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
- (2013) Z. Cheng et al. CLINICAL CANCER RESEARCH
- BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
- (2013) P. Bandopadhayay et al. CLINICAL CANCER RESEARCH
- MicroRNA-34c Inversely Couples the Biological Functions of the Runt-related Transcription Factor RUNX2 and the Tumor Suppressor p53 in Osteosarcoma
- (2013) Margaretha van der Deen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
- (2013) A. C. Belkina et al. JOURNAL OF IMMUNOLOGY
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
- (2012) C. J. Ott et al. BLOOD
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines
- (2012) Claudia M.J. Lucero et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions
- (2012) David S. Hewings et al. JOURNAL OF MEDICINAL CHEMISTRY
- A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength
- (2012) Marc Baud’huin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
- (2012) W. W. Lockwood et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Place your BETs: the therapeutic potential of bromodomains
- (2012) R.K. Prinjha et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages
- (2011) A. Yarilina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Direct anti-cancer effect of oncostatin M on chondrosarcoma
- (2010) Emmanuelle David et al. INTERNATIONAL JOURNAL OF CANCER
- Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma
- (2010) E. Kobayashi et al. MOLECULAR CANCER THERAPEUTICS
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis
- (2010) T Shimizu et al. ONCOGENE
- Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss ofCdkn2
- (2009) Alexander B Mohseny et al. JOURNAL OF PATHOLOGY
- Oncostatin M Induces Bone Loss and Sensitizes Rat Osteosarcoma to the Antitumor Effect of Midostaurin In vivo
- (2008) B. Brounais et al. CLINICAL CANCER RESEARCH
- Interleukin-6 Inhibits Receptor Activator of Nuclear Factor κB Ligand-Induced Osteoclastogenesis by Diverting Cells into the Macrophage Lineage: Key Role of Serine727Phosphorylation of Signal Transducer and Activator of Transcription 3
- (2008) Laurence Duplomb et al. ENDOCRINOLOGY
- Brd4 Coactivates Transcriptional Activation of NF- B via Specific Binding to Acetylated RelA
- (2008) B. Huang et al. MOLECULAR AND CELLULAR BIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started